Seven other companies are scheduled for the week of
The manager and joint managersare
EGRX scheduled a
For the three months ended December '13 revenue increased 267% to
EGRX's collaborators include
The growth plan is to develop additional applications and sell worldwide without partners.
EGRX has 2 approved products, 6 advanced products, two major collaborators and a growth plan to proceed without partners over time.
Royalty and product sales are both showing very good growth.
Existing stockholders indicate an interest in buying
The future looks promising for EGRX so the IPO rating is a buy.
EGRX is a specialty pharmaceutical company focused on developing and commercializing injectable products utilizing the
EGRX's business model is to develop proprietary innovations to
2 approved products, 6 advanced product candidates
As a result, EGRX's disclosed product portfolio now includes two approved products and six advanced product candidates. EGRX currently has one commercialized product, EP-1101 (argatroban).
Due to limited financial resources, EGRX initially decided to collaborate with a commercial partners in order to commercialize EP-1101 (argatroban)and it is now currently marketed by
As a result of its commercialization strategy, EGRX has been able to minimize certain expenses, but also is required to share revenues from EP-1101 (argatroban) with its commercial partners.
For each of its products, EGRX intends to enter the market no later than the first generic drug, allowing it to substantially convert the market to its product by addressing the needs of stakeholders who ultimately use its products.
EGRX believes it can further extend commercial duration through new intellectual property protection and/or orphan drug exclusivity and three years of regulatory exclusivity as provided under the Hatch-Waxman Act, as applicable.
Since its inception, EGRX has focused on identifying attractive product candidates for its approach under the 505(b)(2) regulatory pathway.
In the future, EGRX intends to commercialize products independently in
As part of this strategy, EGRX intends to establish a small, specialty sales force that will target group purchasing organizations, hospital groups and key stakeholders in acute care settings, primarily hospitals and infusion centers.
EGRX expects the impact on operating results of this commercialization strategy will be that EGRX will receive revenue from direct sales, and royalty income, and income from collaborative arrangement will be a less significant part of revenues.
EGRX is the exclusive licensee under its license with Lyotropic to a family of patents and applications that relate to low volume formulations of dantrolene, and methods of treatment using dantrolene.
There are three issued U.S. patents, and one pending U.S. patent application, along with foreign counterparts that include both issued patents and pending applications.
The issued U.S. patents (US 8,110,225, US 7,758,890 and US 8,604,072) cover low volume formulations of dantrolene in reconstitutable and in ready to use liquid form. EGRX expects that the issued patents will expire no later than
EGRX is the sole owner of five pending U.S. patent applications, and six corresponding foreign filings for patent applications in a number of jurisdictions covering various formulations and methods of use of bendamustine. EGRX is currently prosecuting these applications, which, if issued, would expire no later than
EGRX is the co-owner, with
EGRX's competitors include organizations such as major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and generic drug companies.
Use of proceeds
EGRX expects to net
the balance for working capital and general corporate purposes.